Alzheimer Disease, Cognitive Impairment, Dementia, Neurocognitive Disorders, Neurodegenerative Diseases
Conditions
Brief summary
The goal of this cohort study is to estimate the incidence of AD in the first-degree relatives of patients with AD. The main questions it aims to answer are: * cognitive changes of subjects at high risk of AD as ageing; * environmental and behavioral factors affecting AD incidence.
Detailed description
This study is a prospective cohort study focusing on the first-degree relatives of patients with Alzheimer's disease (AD). Multiple methods including the neuropsychiatric assessment battery, magnetic resonance imaging (MRI) and fluid biomarkers (blood and urine) are used to estimate the longitudinal changes of the participants at high risk of AD. Besides, a structured questionnaire is designed to investigate how environmental, behavioral and other factors influence the incidence of AD. This study is of great significance in establishing novel guidelines for the prevention and treatment of dementia suitable for Chinese population, and for clinicians to predict the risk of AD in first-degree relatives.
Interventions
None listed
Sponsors
Ruijin Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. the AD diagnostic criteria of probands meet the 2011 National Institute on Aging - Alzheimer's Association framework, and participants are the first-degree relatives (including parents, children and siblings of the same father and mother) of the proband; 2. not patients with dementia; 3. ≥ 50 years, males and females; 4. subjects have lived in Shanghai for more than 1 year and have no plan to move out of Shanghai within 5 years; 5. subjects are able to complete investigation, physical examination, imaging examination and biological specimen collection.
Exclusion criteria
Individuals will be excluded if they have: 1. other diseases which could cause cognitive decline, e.g. cerebrovascular diseases, Creutzfeldt-Jakob disease and Parkinsons disease; 2. history of psychological disorders (according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition); 3. uncorrectable visual or auditory impairment that hampers the completion of related examination. 4. pre-menopausal women will also be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of cognitive impairment at 5 years | 5 years | Number of participants who covert to AD or mild cognitive impairment (MCI) will be recorded to calculate the incidence. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Mini-Mental State Examination (MMSE) at 5 years | 5 years | MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity. |
| Change From Baseline in Montreal cognitive assessment-Basic (MoCA) at 5 years | 5 years | MoCA is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity. |
| Change From Baseline in Boston naming test (BNT) at 5 years | 5 years | MoCA is a screening instrument used to assess object naming function. The total score ranges from 0 to 30, with lower scores indicating greater disease severity. |
| Change From Baseline in the auditory verbal learning test (AVLT) at 5 years | 5 years | AVLT is a screening instrument used to assess the function of memory. The score in long-term memory (N5) ranges from 0 to 12, with lower scores indicating greater disease severity. |
| Change From Baseline in Geriatric Depression Scale (GDS) at 5 years | 5 years | GDS is a neuropsychological scale used to assess the level of depression. The total score ranges from 0 to 30, with higher scores indicating greater disease severity. |
| Change From multi-modal MRI neuroimaging at 5 years | 5 years | Evaluation of multimodal MRI, including high-resolution structural T1 imaging, functional MRI, diffusion tensor imaging and quantitative susceptibility mapping. |
| Change From Baseline in trail making test (TMT) at 5 years | 5 years | AVLT is a screening instrument used to assess the executive function. Time consumed is recorded as the result, with higher scores indicating greater disease severity. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Blood concentration of Phosphorylated Tau (p-tau) at 5 years | 5 years | Blood p-tau 181 and p-tau 217 at baseline will be tested. The higher blood p-tau is a strong predictor for AD. |
| Change From Baseline in Blood Concentration of Amyloid β (Aβ) at 5 years | 5 years | Blood Aβ40 and Aβ42 at baseline will be tested. The decreased blood Aβ42/40 ratio is a strong predictor for AD. |
Countries
China
Contacts
Primary ContactGang Wang, MD, PhD
Outcome results
None listed